Pluri is a biotechnology company that uses a proprietary 3D cell expansion platform to grow human, plant, and animal cells. Pluri operates an industrial-scale GMP cell manufacturing facility in Haifa, Israel, supporting two primary divisions: Human Health and Longevity, and Foodtech and Bio-Farming. In healthcare, Pluri develops placenta-derived cell therapy candidates, including PLX-PAD for knee osteoarthritis and MAIT cells for solid tumors. Pluri also provides fee-for-service contract development and manufacturing services to biopharma clients via PluriCDMO, and commercializes skincare products through Cellav. In foodtech, Pluri applies its platform through subsidiaries to develop cultivated meat systems (Ever After Foods), cell-cultured coffee (Coffeesai), and cell-cultured cacao (Kokomodo). Pluri is primarily development-stage, with PluriCDMO generating its main commercial revenue. Pluri's business model focuses on CDMO service fees, product sales to aesthetics clinics and distributors, B2B technology and ingredient sales to food producers, and the future commercialization or licensing of its therapeutic candidates.